» Articles » PMID: 38480975

Romidepsin Exhibits Anti-esophageal Squamous Cell Carcinoma Activity Through the DDIT4-mTORC1 Pathway

Overview
Date 2024 Mar 14
PMID 38480975
Authors
Affiliations
Soon will be listed here.
Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common human malignancies worldwide and is associated with high morbidity and mortality. Current treatment options are limited, highlighting the need for development of novel effective agents. Here, a high-throughput drug screening (HTS) was performed using ESCC cell lines in both two- and three-dimensional culture systems to screen compounds that have anti-ESCC activity. Our screen identified romidepsin, a histone deactylase inhibitor, as a potential anti-ESCC agent. Romidepsin treatment decreased cell viability, induced apoptosis and cell cycle arrest in ESCC cell lines, and these findings were confirmed in ESCC cell line-derived xenografted (CDX) mouse models. Mechanically, romidepsin induced transcriptional upregulation of DNA damage-inducible transcript 4 (DDIT4) gene by histone hyperacetylation at its promoter region, leading to the inhibition of mammalian target of rapamycin complex 1 (mTORC1) pathway. Furthermore, romidepsin exhibited better efficacy and safety compared to the conventional therapeutic drugs in ESCC patient-derived xenografted (PDX) mouse models. These data indicate that romidepsin may be a novel option for anti-ESCC therapy.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Reichenbach Z, Murray M, Saxena R, Farkas D, Karassik E, Klochkova A . Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res. 2019; 144:95-135. DOI: 10.1016/bs.acr.2019.05.004. View

3.
Codipilly D, Qin Y, Dawsey S, Kisiel J, Topazian M, Ahlquist D . Screening for esophageal squamous cell carcinoma: recent advances. Gastrointest Endosc. 2018; 88(3):413-426. PMC: 7493990. DOI: 10.1016/j.gie.2018.04.2352. View

4.
Hirano H, Kato K . Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019; 49(5):412-420. DOI: 10.1093/jjco/hyz034. View

5.
Kondo J, Inoue M . Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells. 2019; 8(5). PMC: 6562517. DOI: 10.3390/cells8050470. View